Biodesix, Inc. (BDSX)
NASDAQ: BDSX · IEX Real-Time Price · USD
1.575
+0.015 (0.96%)
At close: May 17, 2024, 4:00 PM
1.650
+0.075 (4.76%)
After-hours: May 17, 2024, 5:21 PM EDT
Biodesix Revenue
Biodesix had revenue of $54.85M in the twelve months ending March 31, 2024, with 34.70% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $14.82M with 63.63% year-over-year growth. In the year 2023, Biodesix had annual revenue of $49.09M with 28.46% growth.
Revenue (ttm)
$54.85M
Revenue Growth
+34.70%
P/S Ratio
3.28
Revenue / Employee
$252,760
Employees
217
Market Cap
180.06M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 49.09M | 10.88M | 28.46% |
Dec 31, 2022 | 38.21M | -16.29M | -29.89% |
Dec 31, 2021 | 54.51M | 8.95M | 19.64% |
Dec 31, 2020 | 45.56M | 21.01M | 85.55% |
Dec 31, 2019 | 24.55M | 4.12M | 20.16% |
Dec 31, 2018 | 20.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Lifecore Biomedical | 103.27M |
OptiNose | 74.02M |
CVRx, Inc. | 42.09M |
Stereotaxis | 27.10M |
Abeona Therapeutics | 3.50M |
Orchestra BioMed Holdings | 2.22M |
BDSX News
- 10 days ago - Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management - Business Wire
- 11 days ago - Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference - Business Wire
- 24 days ago - Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 - Business Wire
- 5 weeks ago - Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting - Business Wire
- 6 weeks ago - Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement - Business Wire
- 7 weeks ago - Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center - Business Wire
- 2 months ago - Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights - Business Wire
- 2 months ago - Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference - Business Wire